A strain of Baltic Lactobacillus citrinum BMD-07 and its application
By inhibiting ETEC biofilm formation using Baltic Lactobacillus citrate BMD-07 and its fermentation products, the problem of poor inhibition effect in existing technologies has been solved, and the stability and safety have been improved, making it suitable for the preparation of products that inhibit ETEC.
Patent Information
- Application Number
- CN202611586818.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-14
- Publication Date
- 2026-11-10
AI Technical Summary
Existing antibiotic interventions have limited effectiveness and are difficult to effectively inhibit the formation of enterotoxigenic Escherichia coli (ETEC) biofilms. Furthermore, existing active substances lack stability and there is a lack of microbial resources that combine probiotic properties with safety.
A strain of Baltic Lactobacillus citrica BMD-07 and its fermentation products were provided. The cell-free fermentation supernatant can inhibit ETEC biofilm formation, mainly acting on the early adhesion stage, and has good stability, probiotic properties and safety.
It significantly inhibits ETEC biofilm formation, reduces the number of biofilm-covered bacteria, has strong self-aggregation ability, is resistant to high temperature, acidic environment and simulated gastrointestinal fluid, adapts to feed processing and gastrointestinal environment, has good safety, and is suitable for the preparation of microecological preparations, feed additives and veterinary preparations.
Smart Images

Figure CN123063320A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of microbial technology, and more particularly to a strain of Baltic Lactobacillus citrica-D-07 and its applications. Background Technology
[0002] Enterotoxigenic Escherichia coli Escherichia coli E. coli (ETEC) is a significant pathogen causing diarrhea and intestinal damage in livestock and poultry farming. Once it forms a biofilm, its environmental tolerance, drug resistance, and ability to colonize the host increase, leading to persistent infection and making control more difficult. Current antibiotic interventions are limited in effectiveness and do not meet the requirements for antibiotic-free farming.
[0003] To address the aforementioned issues, microbial bioactive substances have attracted attention as an antibiotic alternative strategy. However, the effectiveness of these substances in combating ETEC biofilm formation is influenced by the strain source and the properties of the active ingredients, and they generally suffer from insufficient stability. The activity of some bioactive substances decreases after protease or high-temperature treatment, making them difficult to adapt to feed processing and the gastrointestinal environment. Furthermore, existing reports on bioactive substances primarily target post-biofilm clearance, and their intervention effects on the early adhesion stage of biofilm formation remain unclear; strain resources possessing both good probiotic properties and safety are also relatively scarce. Summary of the Invention
[0004] In view of this, the present invention provides a strain of Baltic Lactobacillus citrica BMD-07 and its application. This strain and its cell-free fermentation supernatant can inhibit ETEC biofilm formation, mainly acting on the early adhesion stage of biofilm formation, and also have good stability, probiotic properties and safety.
[0005] In a first aspect, the present invention provides a strain of Baltic Lactobacillus citrica (… Limosilactobacillus balticus BMD-07, the Baltic Lactobacillus citrate BMD-07, was deposited at the China Center for Type Culture Collection on August 31, 2026, with accession number CCTCC NO: M 20262000.
[0006] Secondly, the present invention provides a fermentation product obtained by fermentation of the aforementioned Baltic Lactobacillus citrate BMD-07, wherein the fermentation product is a cell-free fermentation supernatant.
[0007] Thirdly, the present invention provides a method for preparing the above-mentioned fermentation product, comprising the following steps: inoculating the above-mentioned Baltic Lactobacillus citrate BMD-07 into a liquid culture medium and culturing to obtain a fermentation broth; centrifuging the fermentation broth and collecting the supernatant; filtering the supernatant to remove bacteria and obtaining a cell-free fermentation supernatant.
[0008] Fourthly, the present invention provides a microbial inoculant, wherein the active ingredient of the microbial inoculant comprises at least one of the above-mentioned Baltic Lactobacillus citrate BMD-07 cells, fermentation broth, and inactivated cells.
[0009] Fifthly, the present invention provides the application of the above-mentioned Baltic Lactobacillus citrate BMD-07, the above-mentioned fermentation product, the fermentation product prepared by the above-mentioned preparation method, or the above-mentioned microbial agent in the preparation of products that inhibit the formation of enterotoxigenic Escherichia coli biofilms.
[0010] Preferably, the product includes microecological preparations, feed additives, veterinary preparations, or drugs.
[0011] In a sixth aspect, the present invention provides the use of the above-mentioned Baltic Lactobacillus citrate BMD-07, the above-mentioned fermentation product, the fermentation product prepared by the above-mentioned preparation method, or the above-mentioned microbial agent in the preparation of products for the prevention and / or treatment of diseases caused by enterotoxigenic Escherichia coli infection.
[0012] Preferably, the diseases caused by enterotoxigenic Escherichia coli infection include diarrhea, intestinal damage, or decreased production performance in livestock and poultry.
[0013] Preferably, the livestock and poultry include pigs, cattle, sheep, or poultry.
[0014] In a seventh aspect, the present invention provides a method for inhibiting the formation of enterotoxigenic Escherichia coli biofilm, comprising the step of adding the above-mentioned Baltic Lactobacillus citrate BMD-07, the above-mentioned fermentation product, the fermentation product prepared by the above-mentioned preparation method, or the above-mentioned microbial agent to the culture system of enterotoxigenic Escherichia coli.
[0015] Preferably, the addition time is 0-6 h after the start of the enterotoxin-producing Escherichia coli biofilm culture.
[0016] Compared with the prior art, the present invention has achieved the following beneficial effects: The Baltic Lactobacillus citrate provided by this invention ( Limosilactobacillus balticusBMD-07 exhibits a significant ability to inhibit biofilm formation by enterotoxigenic Escherichia coli, reducing the number of biofilm-covered enterotoxigenic Escherichia coli and primarily acting on the early adhesion stage of biofilm formation. This strain possesses strong self-agglutination ability, with a self-agglutination rate exceeding 80%, and a co-agglutination rate with enterotoxigenic Escherichia coli exceeding 50%, facilitating competitive adhesion. It demonstrates good tolerance to high temperatures, acidic environments, bile salts, and simulated gastrointestinal fluids, achieving a survival rate exceeding 60% after treatment with simulated gastrointestinal fluids, thus adapting to feed processing and the gastrointestinal environment. It is sensitive to several commonly used antibiotics, exhibiting good safety. This strain and its fermentation products can be used to prepare microecological preparations, feed additives, veterinary preparations, or drugs that inhibit enterotoxigenic Escherichia coli biofilm formation, making it suitable for the green prevention and control of Escherichia coli diseases in livestock and poultry. Attached Figure Description
[0017] The accompanying drawings, which form part of this specification, are used to provide a further understanding of the invention. The illustrative embodiments and descriptions of the invention are used to explain the invention and do not constitute an undue limitation thereof. Obviously, those skilled in the art can obtain other drawings based on these drawings without any inventive effort.
[0018] In the following figures, lowercase letters a, b, c, etc., indicate statistically significant differences (P<0.05). Groups labeled with the same letter have no significant differences, while groups labeled with different letters have significant differences. ab indicates that this group has no significant differences from groups labeled a and b; bc indicates that this group has no significant differences from groups labeled b and c; cd indicates that this group has no significant differences from groups labeled c and d; ns indicates no significant difference. CFS represents cell-free fermentation supernatant, and ETEC represents enterotoxigenic Escherichia coli.
[0019] Figure 1 The images show the colony morphology of five candidate lactobacilli strains on MRS solid medium in Example 1 of this invention; wherein, (A) is Lactobacillus rhamnosus BMD-01, (B) is Lactobacillus amyloliquefaciens BMD-06, (C) is Lactobacillus citrate BMD-07, (D) is Lactobacillus johnsonii BMD-23, and (E) is Lactobacillus rumenans BMD-24.
[0020] Figure 2 This is a bar chart showing the inhibitory effect of five candidate lactobacilli on ETEC biofilm formation in Example 1 of the present invention; where CON represents the ETEC control group without the addition of candidate lactobacilli.
[0021] Figure 3 This is a phylogenetic tree of BMD-07, a Baltic Lactobacillus citrate, constructed based on the 16S rRNA gene sequence in Example 1 of the present invention.
[0022] Figure 4 This is a bar chart showing the autoagglutination rate of the five candidate lactobacilli strains in Example 2 of the present invention.
[0023] Figure 5 This is a bar chart showing the co-agglutination rate of the five candidate lactobacilli strains with ETEC in Example 2 of the present invention.
[0024] Figure 6 This is a bar chart showing the survival rates of five candidate lactobacilli strains treated at different temperatures in Example 2 of the present invention.
[0025] Figure 7 This is a bar chart showing the survival rates of five candidate lactobacilli strains under different pH conditions in Example 2 of the present invention.
[0026] Figure 8 This is a bar chart showing the survival rates of five candidate lactobacilli strains at different bile salt concentrations in Example 2 of the present invention.
[0027] Figure 9 This is a bar chart showing the survival rates of five candidate lactobacilli strains after treatment with simulated gastrointestinal fluid in Example 2 of this invention.
[0028] Figure 10 This is a bar chart showing the effects of live BMD-07 bacteria, heat-inactivated BMD-07 bacteria, and BMD-07 CFS on ETEC biofilm formation in Example 3 of the present invention; where CON represents the ETEC control group.
[0029] Figure 11 The graph shows the inhibitory effect of BMD-07 CFS on different stages of ETEC biofilm in Example 3 of the present invention. Among them, (A) is a bar graph showing the effect of adding different volume fractions (5%, 10%, 15%, 20%, 30%, v / v) of BMD-07 CFS on biofilm formation in the initial stage of ETEC culture, and (B) is a bar graph showing the effect of adding different volume fractions (5%, 10%, 15%, 20%, 30%, v / v) of BMD-07 CFS on biofilm retention in the mature biofilm stage of ETEC.
[0030] Figure 12 This is a bar chart showing the effect of adding 15% BMD-07 CFS at different time points (0, 2, 4, 6, 8, 10, 12 h) on the final biofilm formation amount in Example 3 of the present invention.
[0031] Figure 13 This is a bar chart showing the anti-biofilm activity of BMD-07 CFS after treatment with proteinase K, papain, trypsin, pepsin and catalase in Example 3 of the present invention. CON represents the ETEC control group without BMD-07 CFS.
[0032] Figure 14 The bar chart shows the anti-biofilm activity of BMD-07 CFS after treatment at different temperatures (40℃, 60℃, 80℃, 100℃, 121℃) in Example 3 of this invention; where CON represents the ETEC control group without the addition of BMD-07 CFS.
[0033] Figure 15 This is a bar chart showing the anti-biofilm activity of BMD-07 CFS under different pH conditions (5.0, 6.0, 7.0) in Example 3 of the present invention; where CON represents the ETEC control group without the addition of BMD-07 CFS. Detailed Implementation
[0034] It should be noted that the following detailed descriptions are exemplary and intended to provide further illustration of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0035] Enterotoxigenic Escherichia coli is an important pathogen causing diarrhea and intestinal damage in livestock and poultry farming. Its biofilm formation can enhance environmental tolerance, drug resistance, and colonization ability. This invention obtained a strain of Baltic Lactobacillus citrate BMD-07 through screening. This strain and its fermentation products can inhibit the biofilm formation of enterotoxigenic Escherichia coli and also have good stability, probiotic properties, and safety.
[0036] The first aspect of this invention provides a strain of Baltic Lactobacillus citrinum ( Limosilactobacillus balticus BMD-07, the Baltic Lactobacillus citrate BMD-07, was deposited at the China Center for Type Culture Collection on August 31, 2026, with accession number CCTCC NO: M 20262000, and the deposit address is No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, China.
[0037] In some embodiments, the Baltic Lactobacillus citrate BMD-07 is isolated from the intestines of healthy animals or samples from the culture environment, and obtained through streak plating on MRS solid medium, anaerobic culture, and single-colony purification. The strain forms grayish-white or slightly yellow, translucent colonies with smooth surfaces, regular edges, and slightly raised centers on MRS solid medium.
[0038] The Baltic *Lactobacillus citrate* BMD-07 strain possesses the ability to inhibit biofilm formation by enterotoxigenic *Escherichia coli*. In some embodiments, this inhibition manifests as a reduction in the number of biofilm-covered enterotoxigenic *E. coli*. The strain also exhibits good self-agglutination ability, with a self-agglutination rate exceeding 80%; and a co-agglutination rate with enterotoxigenic *E. coli* exceeding 50%. The strain demonstrates good tolerance to high temperatures, acidic environments, bile salts, and simulated gastrointestinal fluids, with a survival rate exceeding 60% after treatment with simulated gastrointestinal fluids. The strain shows sensitivity or high sensitivity to one or more commonly used antibiotics, including imipenem, chloramphenicol, doxycycline, florfenicol, azithromycin, minocycline, and tetracycline.
[0039] A second aspect of this invention provides a fermentation product obtained from the fermentation of *Lactobacillus citraceus* BMD-07 from the Baltic Sea, wherein the fermentation product is a cell-free fermentation supernatant. The cell-free fermentation supernatant refers to the supernatant obtained by culturing *Lactobacillus citraceus* BMD-07, centrifuging to remove bacterial cells, and then filtering to remove bacteria. The fermentation product retains metabolically active substances produced during the fermentation process of *Lactobacillus citraceus* BMD-07.
[0040] In some embodiments, the cell-free fermentation supernatant possesses one or more of the following properties: it retains its anti-enterotoxigenic Escherichia coli biofilm formation activity after treatment at 121°C for 20 min; its anti-enterotoxigenic Escherichia coli biofilm formation activity does not significantly decrease after treatment with proteinase K, papain, trypsin, pepsin, or catalase; and its anti-enterotoxigenic Escherichia coli biofilm formation activity at pH 5.0 is stronger than that at pH 6.0 and pH 7.0. The cell-free fermentation supernatant can be further concentrated, freeze-dried, or spray-dried to produce a powdered fermentation product for easy storage, transportation, and formulation.
[0041] The third aspect of the present invention provides a method for preparing the above-mentioned fermentation product, comprising the following steps: inoculating the above-mentioned Baltic Lactobacillus citrate BMD-07 into a liquid culture medium and culturing to obtain a fermentation broth; centrifuging the fermentation broth and collecting the supernatant; filtering the supernatant to remove bacteria and obtaining a cell-free fermentation supernatant.
[0042] In some embodiments, the liquid culture medium is MRS liquid culture medium. The inoculum amount can be 0.5% to 5% (v / v), preferably 1% to 3% (v / v), for example, any single value or a range of any two values from 1%, 2%, and 3%, more preferably 2%. The culture temperature can be 35 to 40°C, preferably 36 to 38°C, for example, any single value or a range of any two values from 36°C, 36.5°C, 37°C, 37.5°C, and 38°C, more preferably 37°C. The culture method can be anaerobic culture. The culture time can be 12 to 48 h, preferably 18 to 36 h, for example, any single value or a range of any two values from 18 h, 24 h, 30 h, and 36 h, more preferably 24 h.
[0043] In some embodiments, the filtration and sterilization can use a filter membrane with a pore size of 0.10~0.45 μm, preferably 0.20~0.22 μm, for example, it can be any single value or a range of any two values between 0.20 μm and 0.22 μm, and more preferably 0.22 μm.
[0044] In some embodiments, the preparation method further includes activating *Lactobacillus citraceus* BMD-07 from the Baltic Sea before fermentation. The activation includes inoculating the preserved *Lactobacillus citraceus* BMD-07 from the Baltic Sea into MRS liquid medium, anaerobically culturing at 35–40°C for 12–48 h, preferably at 37°C for 24 h, and subculturing 1–3 times under the same conditions. The preservation can be done at -80°C or by freeze-drying.
[0045] A fourth aspect of this invention provides a microbial agent, the active ingredient of which comprises at least one of the following: Baltic *Lactobacillus citraceus* BMD-07 cells, fermentation broth, and inactivated cells. In some embodiments, the active ingredient of the microbial agent comprises at least one of the following: Baltic *Lactobacillus citraceus* BMD-07 cells, fermentation broth, or inactivated cells. The fermentation broth can be a culture obtained by culturing Baltic *Lactobacillus citraceus* BMD-07 in a liquid culture medium. The inactivated cells can be obtained by heat treatment, ultraviolet treatment, or chemical inactivation, preferably by heat treatment, for example, treatment at 60-121°C for 10-30 min. The microbial agent can be a liquid agent or a solid agent. The solid agent can be prepared by freeze-drying, spray drying, or mixing with a carrier. The carrier can include one or more of wheat bran, corn flour, calcium carbonate, starch, lactose, and skim milk powder. The microbial agent may also contain one or more of the following: freeze-drying protectant, antioxidant, stabilizer, or diluent.
[0046] The fifth aspect of the present invention provides the use of the above-mentioned Baltic Lactobacillus citrate BMD-07, the above-mentioned fermentation product, the fermentation product prepared by the above-mentioned preparation method, or the above-mentioned microbial agent in the preparation of products that inhibit the formation of enterotoxigenic Escherichia coli biofilms.
[0047] Preferably, the product includes a microecological preparation, a feed additive, a veterinary preparation, or a drug. The microecological preparation may contain live, inactivated, or fermentation products of *Lactobacillus citrate* BMD-07 from the Baltic Sea, and may further contain prebiotics, carriers, or excipients. The feed additive may be added to animal feed in the form of powder, granules, or premix. The veterinary preparation may be administered orally, for example, through drinking water or by mixing with feed. The drug may contain pharmaceutically acceptable excipients or carriers, such as one or more of physiological saline, phosphate buffer, starch, lactose, and microcrystalline cellulose.
[0048] The sixth aspect of the present invention provides the use of the above-mentioned Baltic Lactobacillus citrate BMD-07, the above-mentioned fermentation product, the fermentation product prepared by the above-mentioned preparation method, or the above-mentioned microbial agent in the preparation of products for the prevention and / or treatment of diseases caused by enterotoxigenic Escherichia coli infection.
[0049] Preferably, the diseases caused by enterotoxigenic Escherichia coli infection include diarrhea, intestinal damage, or decreased production performance in livestock and poultry. Preferably, the livestock and poultry include pigs, cattle, sheep, or poultry. The product can be a drug, feed additive, or probiotic preparation. The viable bacterial concentration of *Lactobacillus citrate* BMD-07 in the product can be 10-1. 5 ~10 9 CFU / mL or CFU / g, preferably 10 6 ~10 8 CFU / mL or CFU / g. The amount of cell-free fermentation supernatant added to the product can be 5% to 30% (v / v), preferably 10% to 20% (v / v), for example, it can be any one value or a range of any two values among 10%, 15%, and 20%, and more preferably 15%.
[0050] A seventh aspect of the present invention provides a method for inhibiting the formation of enterotoxigenic Escherichia coli biofilm, comprising the step of adding the aforementioned Baltic Lactobacillus citrate BMD-07, the aforementioned fermentation product, the fermentation product prepared by the aforementioned preparation method, or the aforementioned microbial agent to a culture system of enterotoxigenic Escherichia coli. Preferably, the addition time is 0-6 hours after the start of enterotoxigenic Escherichia coli biofilm culture.
[0051] In some embodiments, the addition time can be any value or a range of any two values from 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, and 6 h after the start of enterotoxigenic Escherichia coli biofilm culture, preferably 0 to 4 h, and more preferably 0 to 2 h. The culture temperature can be 35 to 40°C, preferably 36 to 38°C, for example, any value or a range of any two values from 36°C, 37°C, and 38°C, and more preferably 37°C. The culture time can be 12 to 48 h, preferably 18 to 36 h, for example, any value or a range of any two values from 18 h, 24 h, 30 h, and 36 h, and more preferably 24 h.
[0052] In some embodiments, the Baltic Lactobacillus citrate BMD-07, fermentation product, or microbial agent can be added to the culture system simultaneously with enterotoxigenic Escherichia coli, or it can be added after pre-culturing the enterotoxigenic Escherichia coli for 0-6 hours. The volume fraction of the fermentation product added to the culture system can be 5%-30% (v / v), preferably 10%-20% (v / v), for example, it can be any one value or a range of any two values from 5%, 10%, 15%, 20%, and 30%, and is more preferably 15%.
[0053] The technical solution of the present invention will be further described below with reference to specific embodiments. The present invention does not impose any special restrictions on the source of reagents used in the following embodiments; commercially available products well known to those skilled in the art can be used.
[0054] The culture medium formulations in the following examples are as follows: MRS solid medium: 10 g peptone, 5 g beef extract, 4 g yeast extract, 20 g glucose, 2 g dipotassium hydrogen phosphate, 2 g triammonium citrate, 5 g sodium acetate, 0.2 g magnesium sulfate, 0.05 g manganese sulfate, 15 g agar, 1 g Tween 80, dissolved in 1000 mL distilled water, pH adjusted to 6.2±0.2.
[0055] MRS liquid culture medium: 10 g peptone, 5 g beef extract, 4 g yeast extract, 20 g glucose, 2 g dipotassium hydrogen phosphate, 2 g triammonium citrate, 5 g sodium acetate, 0.2 g magnesium sulfate, 0.05 g manganese sulfate, 1 g Tween 80, dissolved in 1000 mL distilled water, pH adjusted to 6.2 ± 0.2.
[0056] LB liquid medium: 10 g tryptone, 5 g yeast extract, and 10 g sodium chloride were dissolved in 1000 mL distilled water and the pH was adjusted to 7.0 ± 0.2.
[0057] LB solid medium: Add 15 g of agar to LB liquid medium.
[0058] Eosin methylene blue agar medium is prepared according to conventional formulas or commercially available mediums are used.
[0059] Example 1 This embodiment provides the screening and identification of Baltic Lactobacillus citrate BMD-07.
[0060] 1. Source of strain The five candidate lactobacilli and ETEC strains used in this invention were all deposited and provided by the Engineering Research Center for Animal Major Disease Microecological Vaccines (Drugs) of the Ministry of Education, Jilin Agricultural University. The candidate lactobacilli include: Lactobacillus rhamnosus BMD-01 (… Lacticaseibacillus rhamnosus BMD-01), Lactobacillus amyloliquefaciens BMD-06 ( Lactobacillus amylovorus BMD-06), Baltic Lactobacillus citrate BMD-07 ( Limosilactobacillus balticus BMD-07), Lactobacillus johnsonii BMD-23 ( Lactobacillus johnsonii BMD-23), Lactobacillus rumeniformis BMD-24 ( Ligilactobacillus ruminis BMD-24).
[0061] 2. Activation and culture of bacterial strains Candidate Lactobacillus strains were removed from the -80℃ storage tube and inoculated into MRS liquid medium at a 2% (v / v) inoculum, and cultured anaerobically at 37℃ for 24 h. The activated bacterial culture was then passaged once more at a 2% (v / v) inoculum and kept for future use. ETEC strains were removed from the -80℃ storage tube and inoculated into LB liquid medium at a 2% (v / v) inoculum, and cultured at 37℃ and 220 r / min for 12 h. The activated ETEC strain was then passaged once more at a 2% (v / v) inoculum and kept for future use.
[0062] 3. Morphological observation of the strain The five activated target strains were streaked onto MRS solid medium and anaerobically cultured at 37°C. Colony morphology was then observed, and the results are as follows: Figure 1 As shown, the Baltic *Lactobacillus citrate* BMD-07 colonies are grayish-white or slightly yellow, translucent, with a smooth surface, regular edges, and a slightly raised center. The other four candidate lactobacilli also grew normally and formed their own typical single colonies.
[0063] 4. Screening of ETEC-resistant biofilm-forming lactobacilli An ETEC biofilm model was established using the 96-well plate method. The activated ETEC bacterial culture was adjusted to approximately 1×10⁻⁶. 8 CFU / mL, while adjusting the bacterial cultures of the five candidate Lactobacillus strains to approximately 1×10⁻⁶.8 CFU / mL. Add 100 μL each of ETEC and Lactobacillus bacterial suspension to each well and incubate at 37°C for 24 h. After incubation, discard the airborne bacteria, gently wash with phosphate-buffered saline (PBS), collect the film-coated ETECs adhering to the well walls and bottoms, serially dilute them, spread them on eosin methylene blue agar, and incubate for viable cell count.
[0064] The results are as follows Figure 2 As shown, compared with the ETEC control group (CON) without the addition of candidate lactobacilli, the number of biofilm-coated ETEC viable bacteria in the treatment groups of *Lactobacillus rhamnosus* BMD-01, *Lactobacillus amyloliquefaciens* BMD-06, *Lactobacillus citrinus* BMD-07, and *Lactobacillus rumenans* BMD-24 was significantly reduced (P<0.05). Among them, the BMD-07 treatment group had the lowest number of biofilm-coated ETEC viable bacteria, showing the strongest anti-biofilm potential. The number of viable bacteria in the *Lactobacillus johnsonii* BMD-23 treatment group was not significantly different from that in the control group (P>0.05). Based on the above screening results, BMD-07 was selected as the dominant strain for further identification and evaluation.
[0065] 5. Strain identification The dominant strain BMD-07 obtained through the above screening was identified for its 16S rRNA gene. PCR amplification was performed using the universal primers 27F / 1492R to obtain a 1462 bp gene sequence (nucleotide sequence shown in SEQ ID NO: 1). The obtained sequence was compared with standard strain sequences in the NCBI database to analyze homology, and a phylogenetic tree was constructed using MEGA11 software to determine the species classification of the strain. Phylogenetic analysis was performed using maximum likelihood (ML) and the GTR model. The reliability of the phylogenetic relationships was assessed by repeating the Bootstrap algorithm 1000 times. The constructed phylogenetic tree is shown below. Figure 3 As shown. Identification results indicate that this strain is *Lactobacillus citrate* (Baltic *Lactobacillus* citrinum). Limosilactobacillus balticus ).
[0066] The 16S rDNA region sequence of *Lactobacillus citrate* BMD-07 from the Baltic Sea is shown below (SEQ ID NO:1):
[0067] 6. Preservation of bacterial strains The Baltic Lactobacillus citrate BMD-07 was deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC NO: M 20262000, deposit date August 31, 2026, and address 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province, China.
[0068] Example 2 This embodiment provides an evaluation of the biological characteristics of Baltic Lactobacillus citrate BMD-07.
[0069] 1. Self-aggregation ability After culturing BMD-07 for 20 h, the bacterial cells were collected by centrifugation, resuspended in sterile PBS, and the OD was adjusted. 600 The value is approximately 0.8, denoted as A. After the bacterial suspension has been allowed to stand at room temperature for 6 hours, the OD value of the upper bacterial layer is measured. 600 Let B be the agglutination rate. The agglutination rate (%) = (1 - B / A) × 100%. The result is as follows: Figure 4 As shown, the autoagglutination rate of BMD-07 was 84.49%, which was significantly higher than that of other candidate strains.
[0070] 2. Co-aggregation capability with ETEC Equal volumes of ETEC bacterial suspension and BMD-07 bacterial suspension were mixed and allowed to stand at room temperature for 6 hours. The OD of the upper bacterial suspension was then measured. 600 Calculate the coagulation rate, and the results are as follows: Figure 5 As shown in the figure. The results showed that BMD-07 and ETEC had a co-agglutination rate of 58.98%, exhibiting the strongest co-agglutination ability among the five candidate lactobacilli.
[0071] 3. Environmental tolerance assessment (1) Heat resistance: Five candidate lactobacillus strains were treated at different temperatures for 20 min each, and then cultured at 37℃ for 24 h. The OD was then measured. 600 And calculate the survival rate, the results are as follows Figure 6 As shown in the figure, the survival rates of BMD-07 at 40℃, 50℃, 60℃, and 70℃ are close to 100%, 75%, 54.87%, and 44.48%, respectively, which is the highest among the five candidate bacteria, demonstrating good heat tolerance.
[0072] (2) Acid tolerance: Five candidate Lactobacillus strains were inoculated into MRS liquid medium at pH 2.0, 3.0, 4.0, 5.0 and 6.0, respectively, and cultured for 24 h. The survival rate was calculated with the pH 6.0 group as the control. The results are as follows: Figure 7As shown in the figure, BMD-07 exhibits a survival rate of over 95% at pH 5.0, maintains 65% to 75% at pH 4.0, and still has the highest survival rate among the five candidate bacteria at pH 3.0 and pH 2.0. Its survival rate at pH 3.0 and pH 2.0 is significantly higher than that of BMD-01, BMD-23, and BMD-24, and similar to that of BMD-06, demonstrating good acid tolerance.
[0073] (3) Bile salt tolerance: Five candidate lactobacilli were inoculated into MRS liquid medium with bile salt concentrations of 0% (w / v), 0.1% (w / v), 0.3% (w / v) and 0.5% (w / v), respectively. OD was measured after culture. 600 And calculate the survival rate, the results are as follows Figure 8 As shown, BMD-07 has a survival rate of over 90% under 0.1% bile salt conditions, a survival rate of 67% to 78% under 0.3% bile salt conditions, and a survival rate of 60.08% under 0.5% bile salt conditions, which is comparable to BMD-01 and higher than BMD-06, BMD-23 and BMD-24, demonstrating good bile salt tolerance.
[0074] (4) Simulated gastrointestinal fluid tolerance: Five candidate Lactobacillus bacterial cultures were first treated in simulated gastric fluid containing pepsin at pH 4.0 for 6 h, and then transferred to simulated intestinal fluid containing trypsin at pH 6.0 for 6 h. Subsequently, serial dilutions were performed, plate counts were performed, and the survival rate was calculated. The results are as follows: Figure 9 As shown, the survival rate of BMD-07 was 61.76%, similar to that of BMD-23, and higher than that of BMD-01, BMD-06, and BMD-24. It had the highest survival rate among the five candidate bacteria, demonstrating good tolerance to simulated gastrointestinal fluid.
[0075] 4. Safety evaluation The susceptibility of five candidate lactobacilli strains to various commonly used clinical antibiotics was determined using the agar diffusion method. The results are shown in Table 1.
[0076] Table 1 Results of antibiotic susceptibility testing
[0077] Note: In Table 1, antibiotic sensitivity is determined by the diameter (d) of the inhibition zone of the strain on the culture dish. When d < 5 mm, it is marked as "-" (insensitive); when 5 ≤ d < 15 mm, it is marked as "+" (sensitive); when 15 ≤ d ≤ 30 mm, it is marked as "++" (highly sensitive); and when d > 30 mm, it is marked as "+++" (extremely sensitive).
[0078] Table 1 shows that the five candidate lactobacilli strains exhibited different susceptibility characteristics to the tested antibiotics. Among them, *Lactobacillus citrate* BMD-07 from the Baltic Sea showed sensitivity to imipenem (IPM), chloramphenicol (C), doxycycline (DO), florfenicol (FFC), azithromycin (AZI), minocycline (MI), and tetracycline (TET); however, it showed insensitivity to some drugs, including ciprofloxacin (CIP), vancomycin (VAN), lincomycin (MY), and trimethoprim-sulfamethoxazole (SXT). Overall, BMD-07 did not exhibit widespread aberrant resistance characteristics, had a low risk of transferable resistance, and showed good safety.
[0079] Example 3 This embodiment provides the effective components and mechanism of action of Baltic Lactobacillus citrate BMD-07 in preventing ETEC biofilm formation.
[0080] 1. Analysis of effective ingredients BMD-07 culture medium was centrifuged to separate bacterial cells and cell-free fermentation supernatant (CFS). The bacterial cells were heat-inactivated by treatment at 121℃ for 15 min and then resuspended in PBS to obtain heat-inactivated bacterial cells. The fermentation supernatant was filtered through a 0.22 μm filter to obtain BMD-07 CFS with a pH of approximately 4. The heat-inactivated bacterial cells and BMD-07 CFS were added to the ETEC biofilm formation system, and the number of membrane-covered ETECs was measured after 24 h of incubation. The results are as follows: Figure 10 As shown, compared with the ETEC control group (CON, without heat-inactivated bacteria and BMD-07 CFS), the number of membrane-bound ETECs in the heat-inactivated bacteria group was not significantly different (P>0.05), while the number of membrane-bound ETECs in the BMD-07 live bacteria and CFS treatment groups was significantly decreased (P<0.05). This indicates that the main effective component of BMD-07 in inhibiting ETEC biofilm formation is located in its CFS, rather than in the heat-inactivated bacteria.
[0081] 2. Stages of action of BMD-07 CFS on ETEC biofilm At the initial stage of ETEC culture, 5%, 10%, 15%, 20%, and 30% (v / v) BMD-07 CFS were added, and the biofilm amount was determined by crystal violet staining after 24 h of culture. Results are as follows: Figure 11 As shown in (A), it can be seen that when the amount of CFS added reaches 10% or more, it can significantly inhibit the formation of ETEC biofilm, and it is dose-dependent (P<0.05).
[0082] After a mature biofilm was formed in the ETEC biofilm culture for 24 h, BMD-07 CFS with the same concentration gradient was added for further treatment. Figure 11As shown in (B), the results indicate that there was no significant difference in biofilm retention between the treatment groups and the control group. This suggests that CFS mainly acts on the ETEC biofilm formation process, but has little effect on the removal of already formed mature biofilms.
[0083] Further, 15% BMD-07 CFS was added at 0, 2, 4, 6, 8, 10, and 12 h of ETEC biofilm formation, and the final biofilm mass was measured after 24 h of culture. The results are as follows: Figure 12 As shown in the figure. The results showed that adding CFS within 0–6 h significantly reduced the final biofilm formation; when the addition time was delayed to 8 h and beyond, the inhibitory effect decreased significantly, and the biofilm retention increased significantly (P<0.05). This indicates that BMD-07 CFS mainly acts on the early stage of ETEC biofilm formation, especially the initial adhesion and colonization stages.
[0084] 3. Stability analysis of active ingredients in BMD-07 CFS (1) Exclusion test of protease and catalase: BMD-07 CFS was treated with proteinase K, papain, trypsin, pepsin and catalase respectively. The inhibitory effect on ETEC biofilm formation was then detected. The results are as follows: Figure 13 As shown in the figure. The results showed that compared with the ETEC control group (CON) without BMD-07 CFS, the biofilm content in the CFS group was significantly reduced; after treatment with the above-mentioned protease or catalase, the anti-biofilm activity of CFS did not change significantly (P>0.05). This indicates that the main active substance in BMD-07 CFS that exerts its anti-ETEC biofilm effect has good enzyme stability, and its activity is not dependent on protein substances, nor is it mainly dependent on hydrogen peroxide.
[0085] (2) Thermal stability: BMD-07 CFS was treated at 40℃, 60℃, 80℃, 100℃ and 121℃ for 20 min respectively, and its anti-ETEC biofilm formation activity was then tested. The results are as follows: Figure 14 As shown in the figure. The results showed that after treatment at different temperatures, the CFS group still maintained strong anti-biofilm activity, with no significant difference compared to the untreated CFS group (P>0.05). This indicates that the main anti-biofilm active substances in BMD-07 CFS have good thermal stability and can withstand high-temperature treatment.
[0086] (3) pH stability: After adjusting the pH of CFS to 5.0, 6.0 and 7.0 respectively, its effect on ETEC biofilm formation was detected. The results are as follows: Figure 15As shown in the figure. The results showed that the anti-biofilm activity of CFS was significantly pH-dependent. The pH 5.0 treatment group still showed some inhibitory activity; when the pH increased to 6.0 and 7.0, the amount of ETEC biofilm formation significantly rebounded. This indicates that the anti-biofilm activity of BMD-07 CFS is affected by pH, and the activity is stronger under acidic conditions.
[0087] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A Baltic Lactobacillus citrate ( Limosilactobacillus balticus BMD-07, characterized in that, The Baltic Lactobacillus citrate BMD-07 was deposited at the China Center for Type Culture Collection on August 31, 2026, with accession number CCTCC NO: M 20262000.
2. A fermentation product, characterized in that, It is obtained by fermentation of the Baltic Lactobacillus citrate BMD-07 as described in claim 1, wherein the fermentation product is a cell-free fermentation supernatant.
3. The method for preparing the fermentation product as described in claim 2, characterized in that, The method includes the following steps: inoculating the Baltic Lactobacillus citrate BMD-07 of claim 1 into a liquid culture medium and culturing to obtain a fermentation broth; centrifuging the fermentation broth and collecting the supernatant; filtering the supernatant to remove bacteria and obtaining a cell-free fermentation supernatant.
4. A microbial inoculant, characterized in that, The active ingredient of the microbial agent comprises at least one of the following: the bacterial cells, fermentation broth, and inactivated bacterial cells of the Baltic Lactobacillus citrate BMD-07 as described in claim 1.
5. The use of the Baltic Lactobacillus citrate BMD-07 as described in claim 1, the fermentation product as described in claim 2, the fermentation product prepared by the preparation method as described in claim 3, or the microbial agent as described in claim 4 in the preparation of products that inhibit the formation of enterotoxigenic Escherichia coli biofilms.
6. The application as described in claim 5, characterized in that, The products include microecological preparations, feed additives, veterinary preparations, or drugs.
7. The use of the Baltic Lactobacillus citrate BMD-07 as described in claim 1, the fermentation product as described in claim 2, the fermentation product prepared by the preparation method as described in claim 3, or the microbial agent as described in claim 4 in the preparation of products for the prevention and / or treatment of diseases caused by enterotoxigenic Escherichia coli infection.
8. The application as described in claim 7, characterized in that, Diseases caused by enterotoxigenic Escherichia coli infection include diarrhea, intestinal damage, or decreased production performance in livestock and poultry; the livestock and poultry include pigs, cattle, sheep, or poultry.
9. A method for inhibiting the formation of biofilms from enterotoxigenic Escherichia coli, characterized in that, The method includes the step of adding the Baltic Lactobacillus citrate BMD-07 of claim 1, the fermentation product of claim 2, the fermentation product prepared by the preparation method of claim 3, or the microbial agent of claim 4 to the culture system of enterotoxigenic Escherichia coli.
10. The method as described in claim 9, characterized in that, The addition time is 0-6 h after the start of the enterotoxin-producing Escherichia coli biofilm culture.
